跳到正文
研踪PaperTrail

论文库

检索计算机领域论文,按研究方向、作者或关键词筛选。

部分采集异常
正在读取账号与研究记录…

全站更新概况

+1112新增论文
+875其中 AI 相关
+133已有论文修订
+97新增 AI 导读

arXiv 最近完成扫描:2026-11-20 01:33 · 全站最近入库:2026-11-19 19:09各信源进度 →

统计口径与数据新鲜度

统计 2026-11-19 02:29 — 2026-11-20 02:29(北京时间) · 点击数字查看对应简报;AI 相关包含在新增论文内。

最近完成检查:2026-11-20 01:33最近发现新增版本:2026-11-19 19:09库内论文最新更新时间:2026-11-19 02:59

每分钟刷新已保存的数据。空检查不代表采集异常;新收录可能包含历史论文。AI 导读按新增版本计数。

27,982 已收录论文23,249 AI 相关8,559 有修订112 HF 社区发现

浏览论文库

时间范围跟随排序:版本更新、本站收录或首次发表。最新收录可能包含历史论文。部分信源异常,查看状态 →

找到 5 篇论文 · 按版本更新时间排序上轮扫描起点 2026-11-20 01:31(北京时间)
版本更新 · v2arXiv:2502.18864Google Research

Co-Scientist:加速科学发现的多智能体AI系统

Accelerating scientific discovery with Co-Scientist

Juraj Gottweis, Wei-Hung Weng, Alexander Daryin, Tao Tu, Petar Sirkovic, Artiom Myaskovsky, Grzegorz Glowaty, Felix Weissenberger 等 51 位作者

AI 速读 基于摘要

基于Gemini的多智能体系统Co-Scientist通过生成、批判和进化假设,在生物医学领域辅助科学家发现新知识。

cs.AI · cs.CL · cs.HC · cs.LG · q-bio.OT

查看原文摘要

Scientific discovery is driven by scientists generating novel hypotheses for complex problems that undergo rigorous experimental validation. To augment this process, we introduce Co-Scientist, a multi-agent AI system built on Gemini for structured scientific thinking and hypothesis generation. Co-Scientist aims to help scientists discover new original knowledge. Conditioned on their research objectives and prior scientific evidence, it formulates demonstrably novel research hypotheses for experimental verification. The system's design involves agents continuously generating, critiquing and refining hypotheses accelerated by scaling test-time compute. Key contributions include: (1) a multi-agent architecture with an asynchronous task execution framework for flexible compute scaling; (2) a tournament evolution process for self-improving hypotheses generation. Automated evaluations show continued benefits of test-time compute scaling, improving hypothesis quality over time. While general purpose, we focus the validation in three biomedical applications: drug repurposing, novel target discovery, and explaining mechanisms of anti-microbial resistance. Specifically, Co-Scientist helped identify new drug repurposing candidates and synergistic combination therapies for acute myeloid leukemia, which were validated through in vitro experiments. These real-world validations demonstrate the potential of Co-Scientist to accelerate scientific discovery and usher in an era of AI empowered scientists.

版本更新 · v3arXiv:2509.06503Google Research

An AI system to help scientists write expert-level empirical software

Eser Aygün, Anastasiya Belyaeva, Gheorghe Comanici, Marc Coram, Hao Cui, Jake Garrison, Renee Johnston Anton Kast, Cory Y. McLean 等 42 位作者

原文摘要

The cycle of scientific discovery is frequently bottlenecked by the slow, manual creation of software to support computational experiments\cite{hannay2009how}. To address this, we present Empirical Research Assistance (ERA), an AI system that creates expert-level scientific software whose goal is to maximize a quality metric. The system uses a Large Language Model (LLM) and Tree Search (TS)\cite{silver2016mastering} to systematically improve the quality metric and intelligently navigate the large space of possible solutions. ERA achieves expert-level results when it explores and integrates complex research ideas from external sources. The effectiveness of tree search is demonstrated across a diverse range of tasks. In bioinformatics, ERA discovered 40 novel methods for single-cell data analysis that outperformed the top human-developed methods on a public leaderboard. In epidemiology, ERA generated 14 models that outperformed the CDC ensemble and all other individual models for forecasting COVID-19 hospitalizations. ERA also produced expert-level software for geospatial analysis, neural activity prediction in zebrafish, and numerical solution of integrals, and a novel rule-based construction for time series forecasting. By devising and implementing novel solutions to diverse tasks, ERA represents a significant step towards accelerating scientific progress.

cs.AI · q-bio.QM

版本更新 · v4arXiv:2507.05201Google Research

MedGemma Technical Report

Andrew Sellergren, Sahar Kazemzadeh, Tiam Jaroensri, Atilla Kiraly, Madeleine Traverse, Timo Kohlberger, Shawn Xu, Fayaz Jamil 等 81 位作者

原文摘要

Artificial intelligence (AI) has significant potential in healthcare applications, but its training and deployment faces challenges due to healthcare's diverse data, complex tasks, and the need to preserve privacy. Foundation models that perform well on medical tasks and require less task-specific tuning data are critical to accelerate the development of healthcare AI applications. We introduce MedGemma, a collection of medical vision-language foundation models based on Gemma 3 4B and 27B. MedGemma demonstrates advanced medical understanding and reasoning on images and text, significantly exceeding the performance of similar-sized generative models and approaching the performance of task-specific models, while maintaining the general capabilities of the Gemma 3 base models. For out-of-distribution tasks, MedGemma achieves 2.6-10% improvement on medical multimodal question answering, 15.5-18.1% improvement on chest X-ray finding classification, and 10.8% improvement on agentic evaluations compared to the base models. Fine-tuning MedGemma further improves performance in subdomains, reducing errors in electronic health record information retrieval by 50% and reaching comparable performance to existing specialized state-of-the-art methods for pneumothorax classification and histopathology patch classification. We additionally introduce MedSigLIP, a medically-tuned vision encoder derived from SigLIP. MedSigLIP powers the visual understanding capabilities of MedGemma and as an encoder achieves comparable or better performance than specialized medical image encoders. Taken together, the MedGemma collection provides a strong foundation of medical image and text capabilities, with potential to significantly accelerate medical research and development of downstream applications. The MedGemma collection, including tutorials and model weights, can be found at https://goo.gle/medgemma.

cs.AI · cs.CL · cs.CV

版本更新 · v3arXiv:2603.08448Google DeepMindGoogle Research

A prospective clinical feasibility study of a conversational diagnostic AI in an ambulatory primary care clinic

Peter Brodeur, Jacob M. Koshy, Anil Palepu, Khaled Saab, Ava Homiar, Roma Ruparel, Charles Wu, Ryutaro Tanno 等 48 位作者

原文摘要

Large language model (LLM)-based AI systems have shown promise for patient-facing diagnostic and management conversations in simulated settings. Translating these systems into clinical practice requires assessment in real-world workflows with rigorous safety oversight. We report a prospective, single-arm feasibility study of an LLM-based conversational AI, the Articulate Medical Intelligence Explorer (AMIE), conducting clinical history taking and presentation of potential diagnoses for patients to discuss with their provider at urgent care appointments at a leading academic medical center. 100 adult patients completed an AMIE text-chat interaction up to 5 days before their appointment. We sought to assess the conversational safety and quality, patient and clinician experience, and clinical reasoning capabilities compared to primary care providers (PCPs). Human safety supervisors monitored all patient-AMIE interactions in real time and did not need to intervene to stop any consultations based on pre-defined criteria. Patients reported high satisfaction and their attitudes towards AI improved after interacting with AMIE (p < 0.001). PCPs found AMIE's output useful with a positive impact on preparedness. AMIE's differential diagnosis (DDx) included the final diagnosis, per chart review 8 weeks post-encounter, in 90% of cases, with 75% top-3 accuracy. Blinded assessment of AMIE and PCP DDx and management (Mx) plans suggested similar overall DDx and Mx plan quality, without significant differences for DDx (p = 0.6) and appropriateness and safety of Mx (p = 0.1 and 1.0, respectively). PCPs outperformed AMIE in the practicality (p = 0.003) and cost effectiveness (p = 0.004) of Mx. While further research is needed, this study demonstrates the initial feasibility, safety, and user acceptance of conversational AI in a real-world setting, representing crucial steps towards clinical translation.

cs.HC · cs.AI · cs.CL · cs.LG

新论文 · v1arXiv:2503.06074Google DeepMind

Towards Conversational AI for Disease Management

Anil Palepu, Valentin Liévin, Wei-Hung Weng, Khaled Saab, David Stutz, Yong Cheng, Kavita Kulkarni, S. Sara Mahdavi 等 20 位作者

原文摘要

While large language models (LLMs) have shown promise in diagnostic dialogue, their capabilities for effective management reasoning - including disease progression, therapeutic response, and safe medication prescription - remain under-explored. We advance the previously demonstrated diagnostic capabilities of the Articulate Medical Intelligence Explorer (AMIE) through a new LLM-based agentic system optimised for clinical management and dialogue, incorporating reasoning over the evolution of disease and multiple patient visit encounters, response to therapy, and professional competence in medication prescription. To ground its reasoning in authoritative clinical knowledge, AMIE leverages Gemini's long-context capabilities, combining in-context retrieval with structured reasoning to align its output with relevant and up-to-date clinical practice guidelines and drug formularies. In a randomized, blinded virtual Objective Structured Clinical Examination (OSCE) study, AMIE was compared to 21 primary care physicians (PCPs) across 100 multi-visit case scenarios designed to reflect UK NICE Guidance and BMJ Best Practice guidelines. AMIE was non-inferior to PCPs in management reasoning as assessed by specialist physicians and scored better in both preciseness of treatments and investigations, and in its alignment with and grounding of management plans in clinical guidelines. To benchmark medication reasoning, we developed RxQA, a multiple-choice question benchmark derived from two national drug formularies (US, UK) and validated by board-certified pharmacists. While AMIE and PCPs both benefited from the ability to access external drug information, AMIE outperformed PCPs on higher difficulty questions. While further research would be needed before real-world translation, AMIE's strong performance across evaluations marks a significant step towards conversational AI as a tool in disease management.

cs.CL · cs.AI · cs.LG